Beam Therapeutics Base Editing Platform August 2024

Beam Therapeutics presents its precision genetic medicines platform leveraging base editing technology to develop one-time, curative therapies for rare and common diseases. The presentation outlines the company's pipeline progress, including clinical trials for BEAM-101, BEAM-201, BEAM-301, and BEAM-302, alongside multiple preclinical liver programs.